FINWIRES · TerminalLIVE
FINWIRES

Knight Therapeutics Reports Q1 Beat, Raises 2026 Revenue Guidance

By

-- Knight Therapeutics (GUD.TO) first quarter net earnings and adjusted revenue both jumped, beating forecasts, the company said on Thursday, as it raised its 2026 revenue guidance.

Net income surged 503% to $13.2 million or $0.13 per share, from $2.2 million or $0.02 per share in the previous corresponding quarter. The result beat the consensus mean forecast of $0.03 per share, according to FactSet.

Adjusted revenue, which excludes most one-time items, climbed 68% to $147.6 million, beating the forecast of $114.06 million. The increase was driven by the incremental revenue from the Paladin and Sumitomo portfolios, the growth of the company's promoted products, and the purchasing patterns of certain products including Ambisome deliveries to Brazil's health ministry, it said.

Knight Therapeutics also increased its fiscal 2026 revenue guidance to between $510 million to $525 million in revenues up from $490 million to $510 million. Adjusted EBITDA is expected to be 15% of revenues. The higher revenue outlook is due to better performance of promoted products in several countries including Canada, Mexico and Colombia and improved forecasted LATAM currencies against the Canadian dollar.

Knight shares closed down $0.04, to $7.51 on Wednesday on the Toronto Stock Exchange.

Related Articles

Research

Research Alert: The Carlyle Group Misses On Distributable Earnings In Q1 2026

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CG reported mixed Q1 2026 results with total AUM growing 5% to $475B while fee-earning AUM rose only 1% to $333B. Total segment revenue declined 28% Y/Y with realized performance fees dropping sharply to $62M from $355M a year ago. We believe ALT firms like CG should never be judged on just one quarter of performance, as fee-related earnings, performance fees, fund inflows, and monetizations are asymmetrical quarter-to-quarter, and management highlighted CG's position as the #1 private equity sponsor globally by IPO proceeds since 2024, generating approximately $10B over the past two years. Management expressed strong momentum into the current year despite providing no specific 2026 guidance and an earnings miss in Q1 2026. Inflows were solid at $13.0B in Q1 and $52.5B LTM, underpinned by insurance solutions and asset-backed finance strategies in Global Credit. Deployments totaled $10.0B mostly across Global Credit, while realized proceeds of $12.2B suggest stable market conditions for exits.

$CG
Research

Research Alert: Sempra Q1 2026: Eps Meets At $1.51, Reaffirms Guidance, Asset Sales Progress

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Sempra reported Q1 2026 adjusted EPS of $1.51, up 4.9% and in line with consensus, while revenues of $3.655B declined 3.9% and missed estimates by 11.3% due to lower natural gas revenues at Sempra California. Strong operating performance across utility segments included Sempra Texas earnings up 17.1% to $171M and Sempra Infrastructure earnings rising 18.7% to $216M. We view positively the company's execution of its record $65B five-year capital plan targeting 11% rate base CAGR through 2030, with $3.0B deployed in Q1. Management reaffirmed full-year 2026 EPS guidance of $4.80-5.30 and 2027 guidance of $5.10-5.70, maintaining 7%-9% long-term growth targets. We expect the pending SI Partners and Ecogas transactions to close in Q2-Q3 2026, enabling debt paydown and improving credit metrics while shifting the business mix to 95% regulated utilities. In our view, Sempra remains well-positioned for sustainable earnings growth with strong infrastructure investment and balance sheet optimization initiatives.

$SRE
Sectors

Sector Update: Energy Stocks Decline Pre-Bell Thursday

Energy stocks were lower premarket Thursday, with the State Street Energy Select Sector SPDR ETF (XLE) retreating by 1.6%.The United States Oil Fund (USO) was down 3.5%, while The United States Natural Gas Fund (UNG) was 0.6% lower.Front-month US West Texas Intermediate crude oil was down 4.1% at $91.20 per barrel at the New York Mercantile Exchange. Global benchmark North Sea Brent crude oil fell 3.7% to $97.56 per barrel, and natural gas futures were 1% lower at $2.70 per 1 million British Thermal Units.Shell (SHEL) shares were down nearly 2% in early activity after the company reported lower-than-expected Q1 revenue.Tenaris (TS) shares were 4% lower in premarket activity after the company said its Q2 sales will be affected by lower shipments in the Middle East. Tenaris also named Gabriel Podskubka its chief executive officer.MGE Energy (MGEE) stock was down 4.4% before the opening bell after the company said late Wednesday it has launched an underwritten public offering of $250 million common shares, including about $75 million of shares to be sold directly by the company and roughly $175 million to be sold through forward sale agreements.

$MGEE$SHEL$TS$UNG$USO$XLE